{
  "id": "mhgap#screening_cues_d77f41c7",
  "content": "neurological and substance use disorders, 2015.\n15. Global action plan on the public health response\nGeneva: World Health Organization; 2015\nto dementia 2017–2025. Geneva: World Health\n(https://apps.who.int/iris/handle/10665/204132).\nOrganization; 2017 (https://iris.who.int/\nhandle/10665/259615).\n115\nMental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders\n16. Global alcohol action plan 2022–2030: 23. Atlas: country resources for neurological disorders,\nsecond draft, unedited. Geneva: World Health 2nd edition. Geneva: World Health Organization;\nOrganization; 2021 (https://www.who.int/ 2017 (https://iris.who.int/handle/10665/258947).\npublications/m/item/global-alcohol-action-plan-\n24. Mental health atlas 2020. Geneva: World\nsecond-draft-unedited).\nHealth Organization; 2021 (https://iris.who.int/\n17. Declarations of interest. In: World Health handle/10665/345946).\nOrganization [website]. Geneva: World Health\n25. Agabio R, Saulle R, Rösner S, Minozzi S. Baclofen\nOrganization; 2020 (https://www.who.int/\nfor alcohol use disorder. Cochrane Database Syst\nabout/ethics/declarations-of-interest, accessed\nRev. 2023;(1):CD012557.\n27 September 2023).\n26. The ICD-10 classification of mental and\n18. Alonso-Coello P, Schünemann HJ, Moberg J,\nbehavioural disorders: diagnostic criteria for\nBrignardello-Petersen R, Akl EA, Davoli M et al.\nresearch. Geneva: World Health Organization; 1993\nGRADE Evidence to Decision (EtD) frameworks: a\n(https://iris.who.int/handle/10665/37108).\nsystematic and transparent approach to making\nwell informed healthcare choices. 1: Introduction. 27. American Psychiatric Association. Diagnostic and\nBMJ. 2016;353:i2016 (http://dx.doi.org/10.1136/ statistical manual of mental disorders: DSM-IV.",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "work",
      "screening_cues"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Screening Cues neurological and substance use disorders, 2015.\n15. Global action plan on the public health response\nGeneva: World Health Organization; 2015\nto dementia 2017–2025. Geneva: World Health\n(https://apps.who.int/iris/handle/10665/204132).\nOrganization; 2017 (https://iris.who.int/\nhandle/10665/259615).\n115\nMental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders\n16. Global alcohol action plan 2022–2030: 23. Atlas: country resources for neurological disorders,\nsecond draft, unedited. Geneva: World Health 2nd edition. Geneva: World Health Organization;\nOrganization; 2021 (https://www.who.int/ 2017 (https://iris.who.int/handle/10665/258947).\npublications/m/item/global-alcohol-action-plan-\n24. Mental health atlas 2020. Geneva: World\nsecond-draft-unedited).\nHealth Organization; 2021 (https://iris.who.int/\n17. Declarations of interest. In: World Health handle/10665/345946).\nOrganization [website]. Geneva: World Health\n25. Agabio R, Saulle R, Rösner S, Minozzi S. Baclofen\nOrganization; 2020 (https://www.who.int/\nfor alcohol use disorder. Cochrane Database Syst\nabout/ethics/declarations-of-interest, accessed\nRev. 2023;(1):CD012557.\n27 September 2023).\n26. The ICD-10 classification of mental and\n18. Alonso-Coello P, Schünemann HJ, Moberg J,\nbehavioural disorders: diagnostic criteria for\nBrignardello-Petersen R, Akl EA, Davoli M et al.\nresearch. Geneva: World Health Organization; 1993\nGRADE Evidence to Decision (EtD) frameworks: a\n(https://iris.who.int/handle/10665/37108).\nsystematic and transparent approach to making\nwell informed healthcare choices. 1: Introduction. 27. American Psychiatric Association. Diagnostic and\nBMJ. 2016;353:i2016 (http://dx.doi.org/10.1136/ statistical manual of mental disorders: DSM-IV. Neurological and substance use disorders, 2015. 15."
}